Dissection of the recognition properties of p38 MAP kinase. Determination of the binding mode of a new pyridinyl-heterocycle inhibitor family

Journal of Medicinal Chemistry

Volumn 50, Issue 2, 2007, Pages 283-293

  Soliva, Robert ^a,b,c   Gelpí, Josep Lluis ^a,b,d   Almansa, Carmen ^c   Virgili, Marina ^c   Orozco, Modesto ^a,b,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c Drug Discovery   (Spain)

^d BARCELONA SUPERCOMPUTING CENTER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; HETEROCYCLIC COMPOUND; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRIDINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; ENZYME ACTIVE SITE; ISOMER; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR RECOGNITION; QUANTUM MECHANICS;

EID: 33846404143     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061073h     Document Type: Article

References (53)

1. Dinarello, C. A. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. 1991, 3, 941-948.
2. Feldmann, M. L.; Brennan, F. M.; Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
3. Newton, R. C.; Decicco, C. P. Therapeutic potential and strategies for inhibiting TNF alpha. J. Med. Chem. 1999, 42, 2295-2314.
4. Pugsley, M. K. Etanercept: Immunex. Curr. Opin. Invest. Drugs 2001, 2, 1726.
5. Bondeson, J.; Maini, R. N. Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: The clinical experience with infliximab. Remicade. Int. J. Clin. Pract. 2001, 55, 211.
6. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
7. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discovery 2003, 2, 717-726.
8. Salituro, F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, M. S.-S. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 1999, 6, 807-823.
9. Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.; Brown, M. L.; Pargellis, C. A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP binding pocket. Nat. Struct. Biol. 1997, 4, 311-316.
10. Boehm, J. C.; Adams, J. L. New inhibitors of p38 MAP kinase. Expert Opin. Ther. Patents 2000, 10, 25-37.
11. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Topics Med. Chem. 2002, 2, 1011-1020.
12. de Dios, A.; Shih, C.; Lopez de Urald, e. B.; Sánchez, C.; del Prado, M.; Martin Cabrejas, L. M.; Pleite, S.; Blanco-Urgoiti, J.; Lorite, M. J.; Nevill, C. R., Jr.; Bonjouklian, R.; York, J.; Vieth, M.; Wang, Y.; Magnus, N.; Campbell, R. M.; Anderson, B. D.; McCann, D. J.; Giera, D. D.; Lee, P. A.; Schultz, R. M.; Li, L. C.; Johnson, L. M.; Wolos, J. A. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J Med. Chem. 2002, 48, 2270-2273.
13. McClure, K. F.; Abramov, Y. A.; Laird, E. R.; Barberia, J. T.; Cai, W.; Carty, T. J.; Cortina, S. R.; Danley, D. E.; Dipesa, A. J.; Donahue, K. M.; Dombroski, M. A.; Elliott, N. C.; Gabel, C. A.; Han, S.; Hynes, T. R.; Lemotte, P. K.; Mansour, M. N.; Marr, E. S.; Letavic, M. A.; Pandit, J.; Ripin, D. B.; Sweeney, F. J.; Tan, D.; Tao, Y. Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase. J. Med. Chem. 2005, 48, 5728-37.
14. Cirillo, P. F.; Pargellis, C.; Regan, J. The non-heterocycle classes of p38 MAP kinase inhibitors. Curr. Topics Med. Chem. 2002, 2, 1021-1035.
15. Leftheris, K.; Ahmed, G.; Chan, R.; Dyckman, A. J.; Hussain, Z.; Ho, K.; Hynes, J., Jr.; Letourneau, J.; Li, W.; Lin, S.; Metzger, A.; Moriarty, K. J.; Riviello, C.; Shimshock, Y.; Wen, J.; Wityak, J.; Wrobleski, S. T.; Wu, H.; Wu, J.; Desai, M.; Gillooly, K. M.; Lin, T. H.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Zhang, R.; Diller, D.; Doweyko, A.; Sack, J.; Baldwin, J.; Banish, J.; Dodd, J.; Henderson, I.; Kanner, S.; Schieven, G. L.; Webb, M. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J. Med. Chem. 2004, 47, 6283-91.
16. Regan, J.; Breitfelder, S.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
17. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric bindig site. Nat. Struct. Biol. 2002, 9, 268-272.
18. Almansa, C.; Virgili, M. Pyrazolopyridine Derivatives. International Patent Application WO 2004076450.
19. All IC50s referenced in the paper were determined by Upstate Ltd. (ATP concentration of 100 μM in an enzyme competitive inhibition assay).
20. Kollman, P. A. Free energy calculations: Applications to chemical and biochemical phenomena. Chem. Rev. 1993, 93, 2395-2417.
21. Jorgensen, W. L. The many roles of computation in drug discovery. Science 2004, 303, 1813-1818.
22. Pearlman, D. A.; Charifson, P. S. Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase proteins system. J. Med. Chem. 2001, 44, 3417-3423.
23. Gelpí, J. L.; Kalko, S. G.; Barril, X.; Cirera, J.; de la Cruz, X.; Luque, F. J.; Orozco, M. Classical Molecular Interaction Potentials: Improved Setup Procedure in Molecular Dynamics Simulations of Proteins. Proteins 2001, 45, 428.
24. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. Second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
25. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of sample potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
26. Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges. J. Chem. Phys. 1993, 97, 10269-10280.
27. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AMI: A new general purpose quantum mechanical molecular odel. J. Am. Chem. Soc. 1985, 107, 3902-3909.
28. Aleman, C.; Canela, E. I.; Franco, R.; Orozco, M. A new strategy for the evaluation of force parameters from quantum mechanical computations. J. Comput. Chem. 1991, 12, 664-674.
29. The hydrated systems were subjected to 4000 cycles of energy minimization of water hydrogens; (ii) 4000 cycles of energy minimization of all water molecules; (iii) 2000 cycles of energy minimization of the entire system except the protein; (iv) 2000 cycles of energy minimization of waters, counterions, inhibitor, and all residues lining the ATP binding site (group 1), i.e., residues 27-89, 102-120, 129-190, 193-194, 200-202, 204-209, 211-213, 215-216, 221, 228, and 318-331. The optimized systems were thermalized by increasing the temperature from 150 to 300 K in four steps during 50 ps. They were then equilibrated for 100 ps at constant temperature (T = 300 K). Water, inhibitor, counterions, and all the residues in group 1 were allowed to move during the trajectories.
30. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23, 327-341.
31. Geometries were optimised at the HF/6-31.G* level, and energy was computed at the MP2/6-311++G(d) and MP4/6-31G(d) level for the unsubstituted bicycle (see Figure 2). In the case of compound 13, the ONIOM procedure was applied (ref 32), representing the central bicycle as the higher layer at the MP4/6-31G* level and the rest of the molecule at the HF/6-31G* level (see Figure 2).
32. Dapprich, S.; Komaromi, I.; Byun, K. S.; Morokuma, K.; Frisch, M. J. A new ONIOM implementation in Gaussian 98. Part I. The calculation of energies, gradients, vibrational frequencies and electric field derivatives. THEOCHEM 1999, 461, 1-21.
33. Orozco, M.; Luque, J. L. Theoretical study of the tautomerism and protonation of 7-aminopyrazolopyrimidine in the gas phase and in aqueous solution. J. Am. Chem. Soc. 1995, 117, 1378-1386.
34. Orozco, M.; Canela, E. I.; Mallol, J.; Lluis, C.; Franco, R. Ab initio study of the protonation and the tautomerism of the 7-aminopyrazolopyrimidine molecule. J. Org. Chem. 1990, 55, 753-756.
35. Curutchet, C.; Orozco, M.; Luque, F. J. Solvation in octanol: Parametrization of the continuum MST model. J. Comput. Chem. 2001, 22, 1180-1193.
36. Miertus, S.; Tomasi, J. Aproximate evaluations of the electrostatic free energy and internal energy changes in solution processes. Chem. Phys. 1982, 65, 239-245.
37. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, rev. A.7.; Gaussian, Inc.: Pittsburgh, PA, 1998.
38. Peterson, M.; Poirier, R. MonsterGauss; Department of Biochemistry, University of Toronto: Toronto, Canada: version modified by Cammi, R. and Tomasi, J., 1987, and by Luque, F. J. and Orozco, M., 2004.
39. Kalko, S. G.; Luque, F. J.; Orozco, M. UBEXTRACT Program; University of Barcelona: Barcelona, Spain, 2002.
40. Soliva, R.; Almansa, C.; Kalco, S. G.; Luque, F. J.; Orozco, M. Theoretical studies of the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site? J. Med. Chem. 2003, 46, 1372-82.
41. Mehler, E. L.; Solmajer, T. Electrostatic effects in proteins: Comparison of dielectric and charge models. Protein Eng. 1991, 4, 903-910.
42. 3 in this work) which is assumed to remove water in its environment. The desolvation penalty is then determined by integrating the solvation density as computed by the SEDO version of the Poisson-Boltzmann method (see ref 43).
43. Arora, N.; Bashford, D. Solvation energy density occlusion approximation for evaluation of desolvation penalties in biomolecular interactions. Proteins 2001, 43, 12-27.
44. Protein Data Bank. http://www.rcsb.org/pdb.
45. Scapin, G.; Patel, S. B.; Lisnock, J.; Becker, J. W.; LoGrasso, P. V. The structure of JNK3 in complex with small molecule inhibitors: Structural basis for potency and selectivity. Chem. Biol. 2003, 10, 705-712.
46. Colominas, C.; Luque, F. J.; Orozco, M. Tautomerism and protonation of guanine and cytosine. Implications in the formation of triplex DNA. J. Am. Chem. Soc. 1996, 118, 6811-6821.
47. Trygubenko, S. A.; Bogdan, T. V.; Sponer, J.; Rueda, M.; Orozco, M.; Luque, F. J.; Slavíek, P.; Hobza, P. Correlated ab initio study of nucleic acid bases and their tautomers in the gas phase and aqueous solition.1. Cytosine. Phys. Chem Chem. Phys. 2002, 4, 4192-4203.
48. (a) Ribas, J.; Cubero, E.; Luque, F. J.; Orozco, M. Theoretical study of alkyl-PI and aryl-PI interactions. Reconciling theory and experiment. J. Org. Chem. 2002, 67, 7057-7065.
49. (b) Tsuzuki, S.; Honda, K.; Uchimaru, T.; Mikami, M.; Tanabe, K. Origin of the attraction and directionality of the NH/PI interaction: Comparison with the OH/PI and CH/PI interactions. J. Am. Chem. Soc. 2000, 122, 11450.
50. Gum, R. J.; McLaughlin, M. M.; Kumar, S.; Wang, Z.; Bower, M. J.; Lee, J. C.; Adams, J. L.; Livi, G. P.; Goldsmith, E. J.; Young, P. R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 1998, 273, 15605-15610.
51. Young, P. R.; McLaughlin, M. M.; Kumar, S.; Kassis, S.; Doyle, M. L.; McNulty, D.; Gallagher, T. F.; Fisher, S.; McDonnell, P. C.; Carr, S. A.; Huddleston, M. J.; Seibel, G.; Porter, T. G.; Livi, G. P.; Adams, J. L.; Lee, J. C. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 1997, 272, 12116-12121.
52. B).
53. Dominguez, C.; Tamayo, N.; Zhang, D. P38 inhibitors: beyond pyridinylimidazoles. Expert Opin. Ther. Patents 2005, 15, 801-816.